KEGG   DRUG: Sotrovimab
Entry
D12014                      Drug                                   
Name
Sotrovimab (USAN/INN);
Sotrovimab (genetical recombination) (JAN);
Xevudy (TN)
Formula
C6492H10060N1744O2038S40
Exact mass
146340.5997
Mol weight
146430.48
Sequence
(Heavy chain)
QVQLVQSGAE VKKPGASVKV SCKASGYPFT SYGISWVRQA PGQGLEWMGW ISTYQGNTNY
AQKFQGRVTM TTDTSTTTGY MELRRLRSDD TAVYYCARDY TRGAWFGESL IGGFDNWGQG
TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF PEPVTVSWNS GALTSGVHTF
PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP
APELLGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK
PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT
LPPSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSKL
TVDKSRWQQG NVFSCSVLHE ALHSHYTQKS LSLSPGK
(Light chain)
EIVLTQSPGT LSLSPGERAT LSCRASQTVS STSLAWYQQK PGQAPRLLIY GASSRATGIP
DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QHDTSLTFGG GTKVEIKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(Disulfide bridge: H22-H96, H154-H210, H230-L214, H236-H'236, H239-H'239, H271-H331, H377-H435, H'22-H'96, H'154-H'210, H'230-L'214, H'271-H'331, H'377-H'435, L23-L89, L134-L194, L'23-L'89, L'134-L'194)
  Type
Peptide
Class
Antiviral
 DG03174  Anti-SARS-CoV-2 agent
Remark
Therapeutic category: 6250
ATC code: J06BD05
Product: D12014<JP>
Efficacy
Antiviral
  Disease
COVID-19 [DS:H02398]
  Type
Monoclonal antibody
Target
SARS-CoV-2 spike glycoprotein [KO:K24152]
  Pathway
ko03230  Viral genome structure
ko03262  Virion - Coronavirus
ko05171  Coronavirus disease - COVID-19
  Network
nt06171  SARS coronavirus 2 (SARS-CoV-2)
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 J ANTIINFECTIVES FOR SYSTEMIC USE
  J06 IMMUNE SERA AND IMMUNOGLOBULINS
   J06B IMMUNOGLOBULINS
    J06BD Antiviral monoclonal antibodies
     J06BD05 Sotrovimab
      D12014  Sotrovimab (USAN/INN) <JP>
Therapeutic category of drugs in Japan [BR:br08301]
 6  Agents against pathologic organisms and parasites
  62  Chemotherapeutics
   625  Antivirals
    6250  Antivirals
     D12014  Sotrovimab (USAN/INN); Sotrovimab (genetical recombination) (JAN)
Drug groups [BR:br08330]
 Antiviral
  DG03174  Anti-SARS-CoV-2 agent
   D12014  Sotrovimab
Drug classes [BR:br08332]
 Antiviral
  DG03174  Anti-SARS-CoV-2 agent
   D12014  Sotrovimab
Antimicrobials [BR:br08307]
 Antivirals
  Entry, fusion or uncoating inhibitor
   Coronavirus spike protein
    D12014  Sotrovimab (USAN/INN) <JP>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D12014
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D12014
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D12014
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D12014
Other DBs
CAS: 2423014-07-5
PubChem: 497620427
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system